Truist Financial Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $205.00

Key Points

• Truist Financial raised its price target for Jazz Pharmaceuticals from $200 to $205, suggesting a potential upside of 64.75% based on current prices, while maintaining a "buy" rating.
• Despite the positive outlook from Truist, other analysts have mixed ratings, with a recent downgrade from Wall Street Zen from "buy" to "hold" and varying price targets from different firms.
• Jazz Pharmaceuticals reported a significant earnings miss, with EPS of ($8.25) compared to a consensus estimate of ($5.61), while revenues were in line with expectations.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) had its price objective upped by analysts at Truist Financial from $200.00 to $205.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the specialty pharmaceutical company's stock. Truist Financial's price objective would suggest a potential upside of 64.75% from the company's current price.

Other research analysts also recently issued reports about the company. Piper Sandler reaffirmed an "overweight" rating and set a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Royal Bank Of Canada dropped their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Robert W. Baird dropped their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $179.64.

Jazz Pharmaceuticals Stock Down 0.5%

Shares of JAZZ stock opened at $124.43 on Thursday. The firm has a market cap of $7.55 billion, a PE ratio of -18.49, a price-to-earnings-growth ratio of 7.88 and a beta of 0.34. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $148.06. The stock has a 50 day moving average of $113.72 and a 200-day moving average of $117.23.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts predict that Jazz Pharmaceuticals will post 16.96 EPS for the current year.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer owned 436,973 shares of the company's stock, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Hurley Capital LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at $25,000. Elequin Capital LP boosted its stake in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after acquiring an additional 183 shares during the last quarter. Parallel Advisors LLC boosted its stake in Jazz Pharmaceuticals by 85.6% during the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 119 shares during the last quarter. Picton Mahoney Asset Management boosted its stake in Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after acquiring an additional 269 shares during the last quarter. Finally, Spire Wealth Management boosted its stake in Jazz Pharmaceuticals by 137.6% during the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after acquiring an additional 161 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.